First-pass extracted concept

herpes simplex virus vectors

Candidate: concept label1 source documents3 linked claims

Jump to evidence Jump to sources Jump to claims

Live refresh every 5sNext refresh in 5s

Aliases

HSV

Evidence Snippets

Beyond AAV, non-AAV vectors, such as herpes simplex virus (HSV) and adenovirus, are actively explored in cancer trials.

Evidence 1Source 1DOI PubMedprovenance

Supporting Sources

Source 1primary paper2026MEDDOI PubMed

1 evidence snippet 3 linked claims Claim 1 Claim 2 Claim 3

Linked Claims

Claim 1clinical activitysupports2026Source 1DOI PubMed

HSV and adenovirus vectors are actively explored in cancer trials.

Claim 2clinical landscape summarysupports2026Source 1DOI PubMed

Since 2021, the FDA has approved seven new viral vector-based gene therapies.

Claim 3field maturationsupports2026Source 1DOI PubMed

Viral vector technologies are maturing from proof-of-concept studies toward precision platforms capable of addressing rare monogenic disorders and more prevalent complex diseases.